Xeris Biopharma Holdings (XERS) Cash from Operations (2020 - 2026)

Xeris Biopharma Holdings has reported Cash from Operations for 7 years, with the latest figure at 9870000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 198.39% year-over-year to 9870000.0; the trailing twelve-month figure through Mar 2026 stood at 48527000.0 (up 281.69% YoY), and the FY2025 full-year result was 28626000.0, up 177.41% from the prior year.
• Cash from Operations for Q1 2026 stood at 9870000.0, down from 20043000.0 in the prior quarter.
• The five-year high for Cash from Operations was 20043000.0 in Q4 2025, with the low at 48409000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 8729352.94 across 5 years, with a median of 10348000.0 in 2024.
• Annual changes were most pronounced in 2022 — Cash from Operations tumbled 102.07% — and 2025, when it soared 914.84%.
• Xeris Biopharma Holdings' Cash from Operations stood at 16119000.0 in 2022, then jumped by 146.35% to 7471000.0 in 2023, then slumped by 73.56% to 1975000.0 in 2024, then soared by 914.84% to 20043000.0 in 2025, then slumped by 50.76% to 9870000.0 in 2026.
• The last three Cash from Operations figures came in at 9870000.0 (Q1 2026), 20043000.0 (Q4 2025), and 18432000.0 (Q3 2025), per Business Quant data.